Compare Monster Beverage Corp (MNST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Monster Beverage Corp trades at $43.66 (market cap $85.51B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Monster Beverage Corp is far larger — about 8.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MNST | XBI | |
|---|---|---|
Market Cap | $85.51B | $10.11B |
Volume | 8,569,709 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $49.97 | $169.55 |
52-Week Low | $33.16 | $104.99 |
Typical Hold Time | 72 Days | 38 Days |
Enterprise Value | $83.81B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.64, up 1.77% today. The stock exhibits a bullish technical trend, with recent earnings consistently beating estimates. Revenue grew to $8.29 billion in 2025, with a strong net income margin of 23.08%. A recent 1:2 stock split occurred on August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, indicating significant upside potential from current levels.
The outlook is positive, driven by robust international expansion and a debt-free balance sheet. Key risks include intense competition and regulatory challenges, as seen in India. Earnings growth remains the primary catalyst, but the stock's high valuation multiples require sustained performance to justify further gains.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
